BR0207226A - Moduladores de receptores de gaba para tratamento de doenças neurodegenerativas do olho - Google Patents
Moduladores de receptores de gaba para tratamento de doenças neurodegenerativas do olhoInfo
- Publication number
- BR0207226A BR0207226A BR0207226-2A BR0207226A BR0207226A BR 0207226 A BR0207226 A BR 0207226A BR 0207226 A BR0207226 A BR 0207226A BR 0207226 A BR0207226 A BR 0207226A
- Authority
- BR
- Brazil
- Prior art keywords
- gaba receptor
- eye diseases
- receptor modulators
- neurodegenerative eye
- treating neurodegenerative
- Prior art date
Links
- 102000005915 GABA Receptors Human genes 0.000 title abstract 4
- 108010005551 GABA Receptors Proteins 0.000 title abstract 4
- 208000030533 eye disease Diseases 0.000 title abstract 3
- 230000000626 neurodegenerative effect Effects 0.000 title abstract 3
- 102000004300 GABA-A Receptors Human genes 0.000 abstract 1
- 108090000839 GABA-A Receptors Proteins 0.000 abstract 1
- 229940125717 barbiturate Drugs 0.000 abstract 1
- -1 barbiturates Chemical class 0.000 abstract 1
- 150000007656 barbituric acids Chemical class 0.000 abstract 1
- 229940049706 benzodiazepine Drugs 0.000 abstract 1
- 150000001557 benzodiazepines Chemical class 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000002858 neurotransmitter agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229940075993 receptor modulator Drugs 0.000 abstract 1
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical class N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
Abstract
"MODULADORES DE RECEPTORES DE GABA PARA TRATAMENTO DE DOENçAS NEURODEGENERATIVAS DO OLHO". A presente invenção refere-se ao uso de composições farmacêuticas que contêm um modulador de receptores de GABA na oftalmologia, para prevenção e/ou tratamento de doenças neurodegenerativas do olho sendo que os moduladores de receptores de GABA são escolhidos do grupo que compreende benzodiazepinas, ligantes de receptor de benzodiazepina de estrutura diferente, beta-carbolinas, barbituratos, derivados de ácido barbitúrico e/ou neuroesteróides.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10106470 | 2001-02-13 | ||
PCT/EP2002/001537 WO2002078680A1 (de) | 2001-02-13 | 2002-02-13 | Gaba-rezeptor-modulatoren zur behandlung neurodegenerativer erkrankungen des auges |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0207226A true BR0207226A (pt) | 2004-03-09 |
Family
ID=7673764
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0207226-2A BR0207226A (pt) | 2001-02-13 | 2002-02-13 | Moduladores de receptores de gaba para tratamento de doenças neurodegenerativas do olho |
Country Status (10)
Country | Link |
---|---|
US (1) | US20040102438A1 (pt) |
EP (1) | EP1363605A1 (pt) |
JP (1) | JP2004519511A (pt) |
KR (1) | KR20030084926A (pt) |
CN (2) | CN1813723A (pt) |
BR (1) | BR0207226A (pt) |
CA (1) | CA2439842A1 (pt) |
MX (1) | MXPA03007199A (pt) |
WO (1) | WO2002078680A1 (pt) |
ZA (1) | ZA200305817B (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10136842A1 (de) * | 2001-07-23 | 2003-02-13 | Schering Ag | GABA¶A¶-Rezeptor-Modulatoren mit NMDA-antagonistischer Aktivität |
EP2292239A3 (en) * | 2003-04-18 | 2011-03-30 | Advanced Medicine Research Institute | Remedies for diseases to be applied to eye |
WO2004093882A1 (ja) * | 2003-04-18 | 2004-11-04 | Advanced Medicine Research Institute | 眼に適用する疾患治療剤 |
WO2006002836A1 (de) * | 2004-07-01 | 2006-01-12 | Losan Pharma Gmbh | Brausezusammensetzungen von einschlafmitteln |
GB2469339A (en) * | 2009-04-09 | 2010-10-13 | Bambour Omoyiola | Sleep-inducing ophthalmic compositions |
US20120157401A1 (en) * | 2009-05-27 | 2012-06-21 | Ptc Therapeutics, Inc. | Methods for treating neurofibromatosis |
WO2010138758A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating cancer and non-neoplastic conditions |
FR3016881B1 (fr) * | 2014-01-29 | 2016-03-04 | Biocodex | Traitement des degenerescences et des lesions photo-induites de la retine |
EP3664803A4 (en) | 2017-08-01 | 2021-05-05 | PTC Therapeutics, Inc. | DHODH INHIBITOR FOR USE IN THE TREATMENT OF HEMATOLOGICAL CANCERS |
KR101938991B1 (ko) | 2017-09-25 | 2019-01-15 | 강원대학교산학협력단 | 당뇨병성 합병증의 예방 또는 치료용 약제학적 조성물 |
US11020405B2 (en) | 2017-09-25 | 2021-06-01 | Kangwon National University University-Industry Cooperation Foundation | Method for prevention or treatment of diabetic complications |
CN115105512A (zh) * | 2022-08-29 | 2022-09-27 | 中山大学中山眼科中心 | 脱氢表雄酮在制备预防、治疗眼部近视的药物中的用途及其剂型和制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6077839A (en) * | 1992-03-19 | 2000-06-20 | Allergan Sales, Inc. | Method for reducing intraocular pressure in the mammalian eye by administration of gamma aminobutyric acid (GABA) agonists |
-
2002
- 2002-02-13 WO PCT/EP2002/001537 patent/WO2002078680A1/de not_active Application Discontinuation
- 2002-02-13 CN CNA200510130289XA patent/CN1813723A/zh active Pending
- 2002-02-13 CA CA002439842A patent/CA2439842A1/en not_active Abandoned
- 2002-02-13 KR KR10-2003-7010632A patent/KR20030084926A/ko not_active Application Discontinuation
- 2002-02-13 MX MXPA03007199A patent/MXPA03007199A/es unknown
- 2002-02-13 BR BR0207226-2A patent/BR0207226A/pt not_active IP Right Cessation
- 2002-02-13 CN CNA028049012A patent/CN1501795A/zh active Pending
- 2002-02-13 JP JP2002576946A patent/JP2004519511A/ja not_active Withdrawn
- 2002-02-13 US US10/467,897 patent/US20040102438A1/en not_active Abandoned
- 2002-02-13 EP EP02700233A patent/EP1363605A1/de not_active Withdrawn
-
2003
- 2003-07-29 ZA ZA200305817A patent/ZA200305817B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA200305817B (en) | 2004-08-27 |
WO2002078680A1 (de) | 2002-10-10 |
JP2004519511A (ja) | 2004-07-02 |
KR20030084926A (ko) | 2003-11-01 |
EP1363605A1 (de) | 2003-11-26 |
US20040102438A1 (en) | 2004-05-27 |
CN1501795A (zh) | 2004-06-02 |
CN1813723A (zh) | 2006-08-09 |
MXPA03007199A (es) | 2005-02-14 |
CA2439842A1 (en) | 2002-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TNSN00093A1 (fr) | Modulateurs nouveaux des recepteurs de glucocorticoides, procede pour leur preparation et compositions pharmaceutiques les contenant | |
BR0207226A (pt) | Moduladores de receptores de gaba para tratamento de doenças neurodegenerativas do olho | |
TNSN98035A1 (fr) | Atropisomeres de 3-aryl-4(3h)-quinazolinones, procede pour leur preparation et compositions les contenant | |
TNSN99171A1 (fr) | 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant | |
BR9810592A (pt) | Composto, processos para preparar um composto, para tratar ou prevenir doenças do sistema endócrino e para a fabricação de um medicamento, composição farmacêutica, e, uso de um composto | |
TNSN98112A1 (fr) | Composes dipeptidiques | |
TNSN97145A1 (fr) | Derives 6,5-heterobicycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN97192A1 (fr) | Derives de pyrimidine bicycliques condenses, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
BR9812944A (pt) | Inibidores bicìclicos da cinase | |
TNSN97198A1 (fr) | Derives de 6-phenylpyridyl-2- amine et compositions pharmaceutiques les contenant | |
NO304889B1 (no) | Imidazopyridiner og deres anvendelse ved fremstilling av legemidler til behandling av mave-tarm-sykdommer | |
DE59609501D1 (de) | Kristallmodifikation des CDCH, Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen | |
ATE275562T1 (de) | Neue form vom irbesartan, verfahren um diese form zu erhalten und sie enthaltende pharmazeutische zusammensetzungen | |
TNSN99155A1 (fr) | 1-aryl-3-arylmethyl-1,8-naphtyridine-4(1h)-ones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN98024A1 (fr) | 2-amino-6-(2-substitue-4-phenoxy)-substitue-pyridines, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
BR0013009A (pt) | Uso de antagonistas de cgrp e de inibidores de liberação de cgrp para combate a jatos quentes menopáusicos | |
BR9909138A (pt) | Combinação para o tratamento de dependência de álcool e drogas contendo um antagonista de opióide e um modulador de complexo receptor de nmda | |
TNSN99198A1 (fr) | PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT | |
BR0012610A (pt) | Novo derivado de difenilpiperidina | |
BR9809234A (pt) | Composto, composição farmacêutica, uso de um composto, processos para tratar ou prevenir doenças do sistema endocrinológico, para fabricar um medicamento, para preparar um composto e um conjunto, conjunto, e, uso do mesmo. | |
DE59102788D1 (de) | Verwendung von N-alkylierten 1,4-Dihydropyridindicarbonsäureestern als Arzneimittel, neue Verbindungen und Verfahren zu Ihrer Herstellung. | |
BR9813514A (pt) | Agente para tratamento de fibras queratìnicas | |
DE69830450D1 (de) | Neue Atropisomere von 2,3-Disubstituierten-(5,6)-heteroarylkondensierten-pyrimidin-4-onen | |
MA24685A1 (fr) | Derives d'erythromycine tricycliques nouveaux, procede pour leur preparation et composition les contenant | |
BR9914929A (pt) | Fenil - alquenoil - guanidinas substituìdas de ácido biliar, processos para a sua preparação, sua aplicação como medicamentos ou agentes diagnósticos, assim como medicamento contendo as mesmas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5O, 6O E 7O ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2029 DE 24/11/2009. |